PTGS1 and diabetes mellitus: Ageing, type 2 diabetes mellitus (DM), and drug interactions [most common with non-steroidal anti-inflammatory agents (NSAIDs)] at binding site Ser529 of COX-1 reduce the response to aspirin (30) and proton pump inhibitors (PPIs), and myeloproliferative conditions are some of the contributing factors for variability in aspirin responses (31, 32).